RB1 and neoplasm: Note that many different mechanisms can lead to acquired resistance to CDK4/6 inhibitors, including cyclin D–CDK4/6–Rb activation, the activation of other proliferation pathways, the alteration of the tumor microenvironment, and the adjustment of the tumor metabolism [41].